✦ LIBER ✦
570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an IV infusion every 3 weeks to patients with advanced solid tumors
✍ Scribed by R.J. Fram; L.E. Garbo; G.J. Weiss; D. Shkolny; A.V. Yurkovetskiy; C. Bethune; R.K. Ramanathan; M.J. Edelman; E.A. Sausville
- Book ID
- 119603253
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 46 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.